MP
EBAC

Mangrove Partners’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Mangrove Partners’s Portfolio EBAC Stock Details EBAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-39,500
Closed -$383K – 592
2021
Q4 		$383K Hold
39,500
– – 0.02% 473
2021
Q3 		$382K Buy
+39,500
New +$382K 0.03% 331

Other funds holding EBAC

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Mangrove Partners's EBAC Position: Q1 2022 in Review

Mangrove Partners sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2022, closing a stake of 39,500 shares — an estimated $383K sold.

Mangrove Partners first reported a position in EBAC in Q3 2021 and held it in 2 quarters. The position peaked at $383K in Q4 2021. 46 funds tracked by Wall St. Rank hold EBAC as of Q1 2022.

  • Mangrove Partners reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2022 after selling out during the quarter.
  • Mangrove Partners sold 39,500 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2022, an estimated $383K.
  • Mangrove Partners first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q3 2021 and held it in 2 quarters.
  • Mangrove Partners's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $383K in Q4 2021.
  • 46 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2022.

Based on Mangrove Partners's 13F filing for Q1 2022, filed 16 May 2022.